The Transcreener Assay technology is based on the homogenous immunodetection of the nucleotide product of an enzyme reaction. The result is a robust, generic assay platform for the detection of entire families of drug targets.
UDP-glycosyltransferase enzymes catalyze three major classes of reactions, all of interest in drug discovery: biosynthesis of disaccharides or polymers such as starch or hyaluronan, posttranslational modification of proteins, and glucuronidation of small molecules, including endogenous hormones and xenobiotics. One of the major challenges of the pharmaceutical industry is to better predict the pharmacokinetic and pharmacogenomic consequences of drug-metabolizing enzymes, key determinants in drug efficacy and safety.
A broad spectrum of drugs, including opioids, steroidal anti-inflammatories, and antidepressants, are eliminated or activated in the body by glucuronidation. To fulfill the immediate need for high throughput analysis of drug glucuronidation, BellBrook Labs has developed a universal Transcreener™ UGT Far Red Assay.
The Transcreener UGT Far Red assay is a fluorescence polarization immunoassay that detects UDP, the common reaction product formed during the transfer of a sugar moiety from the donor molecule (UDP-sugar) to an acceptor substrate. UDP displaces the tracer from an anti-UDP antibody, resulting in a decrease in polarization. Enzymatic activity is then indicated by a decrease in fluorescence polarization. The inclusion of a far red tracer reduces compound interference and light scatter.
• Universal Homogenous UDP detection
• Predictive Rapid pharmacologically relevant data
• Robust Z’ factor values > 0.6 under initial velocity conditions
• Smart Far red tracer minimizes assay interference
The expanding Transcreener platform now includes universal assays for the detection of ADP, AMP, GMP and UDP.
Contact us at 866.313.7881 or email@example.com for more information or to order the Transcreener UGT Far Red Assay.